Solid Tumor Oncology
Genmab A/S funds clinical research in advanced solid tumors, with activity across non-small cell lung cancer, endometrial cancer, ovarian cancer, cervical cancer, melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma, and triple-negative breast cancer.
- Advanced malignant solid tumors
- Metastatic cutaneous melanoma
- Platinum-resistant ovarian cancer
- Recurrent or metastatic cervical cancer
The portfolio includes studies in both monotherapy and combination therapy settings for recurrent, metastatic, and unresectable disease.
Hematologic Malignancies
The sponsor supports research in B-cell lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, higher-risk myelodysplastic syndrome, and multiple myeloma.
- Relapsed or refractory B-cell lymphoma
- Diffuse large B-cell lymphoma
- Chronic lymphocytic leukemia
- Acute myeloid leukemia
Research activity also spans Richter’s syndrome and other aggressive lymphoid malignancies.
Immuno-Oncology and Antibody-Based Therapies
Clinical programs include immuno-oncology approaches centered on bispecific antibodies, antibody-drug conjugates, and combinations with pembrolizumab or other anticancer agents.
- Checkpoint inhibitor combinations
- T-cell engaging therapies
- Antibody-drug conjugate development
- Combination immunotherapy
These studies cover both hematologic cancers and solid tumors, with attention to anti-tumor activity and safety.
Radiotherapy and Immunoradiotherapy
Genmab also funds research combining radiotherapy with immunotherapy in metastatic solid tumors and advanced endometrial cancer.
- Immunoradiotherapy combinations
- Abscopal response
- Radiation-based combination treatment
- Advanced endometrial carcinoma
These trials reflect interest in integrating local and systemic treatment strategies for difficult-to-treat cancers.
Relapsed and Refractory Disease
A substantial part of the portfolio focuses on relapsed, refractory, and previously treated cancers, including metastatic NSCLC, recurrent endometrial cancer, relapsed/refractory CLL, and relapsed/refractory DLBCL.
- Second- and third-line therapy
- Previously treated metastatic disease
- Recurrent solid tumors
- Refractory hematologic malignancies
Research spans both aggressive lymphomas and advanced solid cancers with limited treatment options.
